1,3-Dibenzyl-5-fluorouracil is used in the research of metabolic bone diseases; it acts as a chemical inhibitor of osteoclastogenesis by downregulating the receptor activator of nuclear factor-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways, thereby suppressing the expression of osteoclast markers.